Overcoming Imposter Syndrome: Improving Your Practice and Teaching by Recognizing and Treating Imposter Syndrome

Wednesday, September 22, 2021, 5:30 PM - 7:00 PM EST

Women and other individuals with marginalized identities experience imposter syndrome in academic medicine, despite their high performance and success. This session will help participants identify and recognize the signs and potential triggers of imposter syndrome and provide actionable steps to combat this issue for practitioners, colleagues, and students.

 This lecture is for Beaumont/OUWB employees and providers only.

1. Recognize the signs of imposter syndrome.
2. Identify the common triggers on the imposter feelings.
3. Employ actionable steps to overcome these symptoms.
4. Demonstrate how to support colleagues and learners suffering from lack of confidence and imposter syndrome.

The session will take place virtually via Zoom

Access Session Here

AMA PRA Category 1 Credits™ (1.50 hours), AMA PRA Non-Physician (Attendance) (1.50 hours), OUWB Meaningful Participation (1.00 hours)

In support of improving patient care, Beaumont Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine CME: Beaumont Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Financial Relationships: Please click the faculty name to view the individual's financial relationships with ineligible companies.

Mitigation of Relevant Financial Relationships

Beaumont Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.